Intravenous anti-P. aeruginosa IgY-antibodies do not decrease pulmonary bacterial concentrations in a porcine model...

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Immunology

Background:

• Ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa is a significant contributor to morbidity and mortality in critically ill patients.
• The increasing prevalence of antimicrobial resistance necessitates the exploration of novel therapeutic strategies against P. aeruginosa infections.

Purpose of the Study:

• To evaluate the efficacy of intravenous administration of specific polyclonal anti-P. aeruginosa IgY antibodies (Pa-IgY) in reducing P. aeruginosa concentrations in the lower airways of a porcine model of VAP.

Main Methods:

• A double-blind, randomized, placebo-controlled porcine model was employed to induce VAP caused by P. aeruginosa.
• Eighteen pigs were randomly assigned to receive either intravenous Pa-IgY or a placebo.
• Physiological parameters and bronchoalveolar lavage (BAL) fluid cultures were monitored over 27 hours.

Main Results:

• The concentration of P. aeruginosa in BAL cultures was comparable between the Pa-IgY intervention group and the placebo control group at the study's conclusion.
• While the intervention group exhibited improved physiological parameters, including higher heart rate, cardiac index, oxygen delivery, and arterial oxygen tension/fraction of inspired oxygen ratio, and lower plasma lactate and blood hemoglobin levels, these did not correlate with reduced bacterial load.

Conclusions:

• Intravenous Pa-IgY, at the dosage administered in this study, did not effectively decrease P. aeruginosa concentrations in the lower airways of a mechanically ventilated porcine model of VAP.
• The observed physiological improvements warrant further investigation but do not confirm therapeutic efficacy for bacterial load reduction in this model.